VALN Valneva SE IFRS
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1836564 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.0%
TTM net income YoY-840.6%
TTM EPS YoY-750.0%
Revenue 3-yr CAGR-21.5%
Net income 3-yr CAGR—
Margins
Gross margin38.7%
Operating margin-47.0%
Net margin-66.0%
FCF margin-32.8%
EBITDA margin—
Returns
ROE-80.2%
ROA-25.6%
ROIC (approx.)-34.5%
Asset turnover0.39x
Leverage & solvency
Liabilities / assets73.4%
Debt / equity1.69x
Current ratio2.38x
Interest coverage-1.96x
Cash quality & payout
Operating cash flow / net income0.46x
Accruals ratio-13.9%
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | 174.66M | 169.58M |
| Cost of revenue | 107.14M | 98.54M |
| Gross profit | 67.52M | 71.04M |
| R&D expense | 85.30M | 74.14M |
| SG&A expense | 37.32M | 42.75M |
| Operating income | -82.06M | 13.33M |
| Interest expense | 41.90M | 23.98M |
| Pretax income | -114.12M | -11.49M |
| Income tax | 1.07M | 761,000 |
| Net income | -115.19M | -12.25M |
| EBITDA | -60.31M | 32.92M |
| EPS (basic) | -0.68 | -0.08 |
| EPS (diluted) | -0.68 | -0.08 |
| Weighted avg. shares (diluted) | 168.18M | 145.71M |
| Balance sheet | ||
| Cash & equivalents | 109.65M | 168.27M |
| Receivables | 27.81M | 35.20M |
| Inventory | 50.23M | 53.66M |
| Current assets | 222.54M | 299.01M |
| PP&E, netmay include right-of-use assets (IFRS) | 119.47M | 138.88M |
| Intangibles | 22.35M | 25.26M |
| Total assets | 398.84M | 500.03M |
| Current liabilities | 93.33M | 114.58M |
| Short-term debt | 17.91M | 20.85M |
| Long-term debt | 161.26M | 166.52M |
| Total debt | 179.17M | 187.37M |
| Total liabilities | 292.67M | 318.78M |
| Shareholders' equity | 106.17M | 181.25M |
| Net debt | 69.52M | 19.10M |
| Shares outstanding | 173.42M | 162.40M |
| Cash flow statement | ||
| Operating cash flow | -52.89M | -67.22M |
| Capital expenditure | 4.42M | 13.87M |
| Free cash flow | -57.31M | -81.08M |
| Investing cash flow | -1.71M | 76.92M |
| Financing cash flow | -621,000 | 30.68M |
| Depreciation & amortization | 21.75M | 19.59M |
| Stock-based compensation | 9.53M | 7.97M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.